Surface Oncology Promotes Goater to CEO, Lynch Remains Chairman

Jeff Goater, chief business officer of Surface Oncology, has been appointed CEO of the company. Goater replaces interim CEO Dan Lynch, who will remain executive chairman of the Cambridge, MA, company’s board of directors. Goater joined Surface a year ago after serving as CFO of Voyager Therapeutics (NASDAQ: [[ticker:VYGR]]) in Cambridge. Surface, which is developing cancer immunotherapies that target the tumor microenvironment, has a partnership with Novartis (NYSE: [[ticker:NVS]]) to develop up to four cancer drugs.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.